Details for Patent: 6,740,664

Title:	Methods for treating otic and ophthalmic infections
Abstract:	Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues. The compositions and methods of the invention are particularly useful in the treatment of acute otitis externa infections and ophthalmic infections attributable to one or both of two newly identified Microbacterium species, Microbacterium otitidis and Microbacterium alconae.
Inventor(s):	Cagle; Gerald (Forth Worth, TX), Abshire; Robert L. (Forth Worth, TX), Stroman; David W. (Irving, TX), McLean; Celeste H. (Fort Worth, TX), Clark; Linda L. (Grandview, TX), Yanni; John M. (Burleson, TX)
Assignee:	Alcon, Inc. (Hunenberg, CH)
Filing Date:	Jun 22, 2001
Application Number:	09/887,775
Claims:	1. A method of treating otic infections or ophthalmic infections attributable to a Microbacterium species selected from the group consisting of Microbacterium otitidis and Microbacterium alconae, which comprises instilling a therapeutically effective amount of an antibiotic composition in the affected ear or eye to eradicate said pathogenic Microbacterium species, said composition comprising an antimicrobial effective amount of a quinolone antibiotic and a pharmaceutically acceptable vehicle therefor. 2. A method according to claim 1, wherein the antibiotic is selected from the group consisting of ciprofloxacin, ofloxacin, gatifloxacin, grepafloxacin, moxifloxacin and trovafloxacin. 3. A method according to claim 2, wherein said composition is instilled in the ear to treat acute otitis externa infections. 4. A method according to claim 2, wherein said composition is instilled in the eye to treat ophthalmic infections. 5. A method according to any one of claims 1-4, wherein the composition further comprises an effective amount of an anti-inflammatory compound. 6. A method according to claim 5, wherein the anti-inflammatory compound comprises a steroidal anti-inflammatory agent. 7. A method according to claim 6, wherein the steroidal anti-inflammatory agent comprises dexamethasone. 8. A method according to claim 5, wherein the anti-inflammatory compound comprises a non-steroidal anti-inflammatory agent. 9. A method according to claim 8, wherein the non-steroidal anti-inflammatory agent is a prostaglandin H synthetase inhibitor. 10. A method according to claim 9, wherein the non-steroidal anti-inflammatory agent comprises diclofenac. 11. A method according to claim 9, wherein the non-steroidal anti-inflammatory agent comprises nepafenac. 12. A method according to claim 9, wherein the non-steroidal anti-inflammatory agent comprises ketorolac. 13. A method according to claim 8, wherein the antibiotic comprises a third generation quinolone antibiotic. 14. A method according to claim 13, wherein the antibiotic comprises moxifloxacin. 15. A method according to claim 14, wherein the non-steroidal anti-inflammatory agent is a prostaglandin H synthetase inhibitor. 16. A method according to claim 14, wherein the non-steroidal anti-inflammatory agent comprises diclofenac. 17. A method according to claim 14, wherein the non-steroidal anti-inflammatory agent comprises nepafenac. 18. A method according to claim 14, wherein the non-steroidal anti-inflammatory agent comprises ketorolac.